We here report results on measurements of IGF-1, IGF-2, and IGFBP-3 from the British United Provident Association (BUPA) prospective study, based on 1051 new cases of cancer at 14 different cancer sites, and we combine the results on prostate, colorectal, and lung cancer with those from published studies in a meta-analysis. This evidence concerns the gene IGFBP3 and lung carcinoma.